Showing results (41-50 of 80) with videos related to

Sort By:
Pageof 8
Cancer Research|August 17, 2005
A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastomaBikul Das, Herman Yeger, Rika Tsuchida, et al.
BMC Cancer|February 26, 2017
Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastomaReza Bayat Mokhtari, Narges Baluch, Micky Ka Hon Tsui, et al.
Journal of Pediatric Hematology/Oncology|October 19, 2018
Prevalence and Clinical Correlations of Somatostatin Receptor-2 (SSTR2) Expression in NeuroblastomaNatasha Alexander, Paula Marrano, Paul Thorner, et al.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2011
A phase 2 trial of trabectedin in children with recurrent rhabdomyosarcoma, Ewing sarcoma and non-rhabdomyosarcoma soft tissue sarcomas: a report from the Children's Oncology GroupSylvain Baruchel, Alberto Pappo, Mark Krailo, et al.
Journal of Pediatric Hematology/Oncology|July 9, 2003
Phase I trial of rebeccamycin analog (NSC #655649) in children with refractory solid tumors: a pediatric oncology group studyAnne-Marie Langevin, Steven D Weitman, John G Kuhn, et al.
Pediatric Blood & Cancer|February 15, 2011
Circulating endothelial cells and circulating endothelial precursor cells in patients with osteosarcomaSteven G DuBois, Diana Stempak, Bing Wu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2005
A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group studyLoretta Lau, Jeffery G Supko, Susan Blaney, et al.
Pediatric Blood & Cancer|August 20, 2013
Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumorsDaniel A Morgenstern, Monia Marzouki, Ute Bartels, et al.
Neoplasia (New York, N.Y.)|May 5, 2009
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse modelLibo Zhang, Kristen M Smith, Amy L Chong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 27, 2011
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumorSushil Kumar, Reza Bayat Mokhtari, Reihaneh Sheikh, et al.
Pageof 8